Search
Displaying 181–190 of 779 for “retinitis clinical trial”
-
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
Research NewsThe Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
-
Foundation Fighting Blindness Provides Public Access to Data From its RUSH2A Natural History Study
Foundation NewsRUSH2A has captured extensive data over four years from patients with USH2A mutations causing non-syndromic retinitis pigmentosa and Usher syndrome type 2A.
-
Research News
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial
Research NewsFirst patient shows vision improvements with a good safety profile.
-
Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
Research NewsIn its fourth year, the meeting is becoming the world’s most comprehensive overview of the promising research underway for emerging IRD treatments.
-
Forty High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
Research NewsIn its fifth year, the Innovation Summit featured 40 presentations from industry experts from around the world.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2020 (July 1, 2019-June 30, 2020)
-
In the Press
Four-year cohort will enroll participants with inherited retinal diseases caused by mutations in the RHO gene. Study is intended to deepen understanding of disease progression and inform future clinical trial design in rhodopsin-associated retinal disease.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2021 (July 1, 2020–June 30, 2021)
-
Seeing Research Advances Firsthand
Beacon StoriesMark does not let his retinitis pigmentosa diagnosis keep him from doing what he loves most, including spending quality time with his family. And in 2019, Mark began participating in a clinical trial, which he describes as life-changing.
